This observation is consistent with the well-established role of PSA as a biomarker for PC detection and monitoring as reported by Boyle et al. [19], who reported a median PSA level of 16.1 ng/mL (IQR: 6.8-87.0 ng/mL) at diagnosis in their cohort of metastatic PC patients. Here, KLK3 is linked to pachyonychia congenita.